Comparison of predictions of the three-state model with experimental data
Agonist | pEC50 | Emaxagonist/Emax 5-HT | L = M = 100 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
IP | AA | IP | AA | KA | KA* | KA** | |||||
Actual | Model | Actual | Model | Actual | Model | Actual | Model | ||||
5-HT | 7.43 | 7.39 | 7.34 | 7.39 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00E-05 | 8.00E-10 | 8.00E-10 |
bufotenin | 6.50 | 6.39 | 6.33 | 6.39 | 0.78 | 0.79 | 1.08 | 1.13 | 1.00E-05 | 1.00E-08 | 7.00E-09 |
DOI | 6.72 | 6.76 | 6.80 | 6.76 | 0.61 | 0.61 | 0.97 | 0.96 | 8.00E-07 | 5.60E-09 | 3.60E-09 |
LSD | 7.80 | 8.09 | 8.11 | 8.09 | 0.17 | 0.16 | 0.39 | 0.40 | 1.10E-08 | 1.00E-09 | 4.00E-10 |
quipazine | 5.89 | 6.04 | 6.06 | 6.04 | 0.89 | 0.89 | 0.59 | 0.60 | 3.50E-06 | 2.00E-08 | 3.00E-08 |
TFMPP | 6.34 | 6.43 | 6.48 | 6.43 | 1.02 | 1.03 | 0.59 | 0.60 | 2.00E-06 | 7.00E-09 | 1.20E-08 |
Computer simulations with the three-state model were done as described in the text. “Actual” data are from experiments with 5-HT2Creceptor-mediated IP accumulation and AA release (Fig. 4 and Table 1). The values obtained from computer simulations (model) closely approximate the experimental data (actual).